NO2864579T3 - - Google Patents

Info

Publication number
NO2864579T3
NO2864579T3 NO13806163A NO13806163A NO2864579T3 NO 2864579 T3 NO2864579 T3 NO 2864579T3 NO 13806163 A NO13806163 A NO 13806163A NO 13806163 A NO13806163 A NO 13806163A NO 2864579 T3 NO2864579 T3 NO 2864579T3
Authority
NO
Norway
Application number
NO13806163A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2864579T3 publication Critical patent/NO2864579T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/225Calcitonin gene related peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57527Calcitonin gene related peptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/585Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO13806163A 2012-01-26 2013-06-18 NO2864579T3 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261591236P 2012-01-26 2012-01-26

Publications (1)

Publication Number Publication Date
NO2864579T3 true NO2864579T3 (enExample) 2018-01-20

Family

ID=47682066

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13806163A NO2864579T3 (enExample) 2012-01-26 2013-06-18

Country Status (14)

Country Link
US (3) US9193776B2 (enExample)
EP (2) EP2807187B1 (enExample)
JP (3) JP6025871B2 (enExample)
KR (2) KR101855242B1 (enExample)
CN (2) CN108997490A (enExample)
AU (2) AU2013211929B2 (enExample)
CA (1) CA2861392C (enExample)
DK (1) DK2807187T3 (enExample)
ES (2) ES2819825T3 (enExample)
IL (2) IL233655A (enExample)
MX (1) MX347229B (enExample)
NO (1) NO2864579T3 (enExample)
RU (2) RU2624016C2 (enExample)
WO (1) WO2013112912A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112912A1 (en) 2012-01-26 2013-08-01 Soares Christopher J Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
JP6538682B2 (ja) * 2013-07-30 2019-07-03 ソアレス クリストファー ジェイ. Cgrpアゴニストペプチド
JO3669B1 (ar) 2015-01-06 2020-08-27 Ferring Bv بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين
JP7360794B2 (ja) * 2016-01-04 2023-10-13 アデプセラ エルエルシー ペプチド類似体
JP7123932B2 (ja) * 2016-09-02 2022-08-23 クリストファー ジェイ. ソアレス 神経保護及び神経疾患におけるcgrp受容体アンタゴニストの使用
CA2967616A1 (en) * 2016-09-19 2018-03-19 The Governors Of The University Of Alberta Brain penetrant amylin receptor based peptides for alzheimer's disease
EP3707157A4 (en) * 2017-11-06 2021-08-18 Auckland Uniservices Limited PEPTIDIC CONJUGATES AS ANAGONISTS OF THE CGRP RECEIVER, THEIR PREPARATION METHODS AND THEIR USES
JP7214100B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214102B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214104B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2046920B1 (enExample) 1969-06-19 1974-05-03 Citizen Watch Co Ltd
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
CH657779A5 (de) 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US4530838A (en) 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS62129297A (ja) * 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
JPS62231168A (ja) 1986-03-21 1987-10-09 ハイブリテツク・インコ−ポレイテツド アナライト−レセプタ−分析用内部標準を設けるための改良法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
JPH07507806A (ja) 1992-06-11 1995-08-31 アルカーメス コントロールド セラピューティクス,インコーポレイテッド エリスロポエチン薬物送達システム
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
WO1994021665A1 (en) 1993-03-24 1994-09-29 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
US5698401A (en) 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
WO1997041223A1 (en) 1996-04-15 1997-11-06 The University Of Miami Molecular clone of cgrp receptor component protein and uses thereof
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
WO2004084859A2 (en) 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
EP2233497A3 (en) * 2004-02-11 2011-01-12 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
CA2584806C (en) 2004-11-01 2014-06-17 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
WO2007055728A1 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2006086769A2 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
EP2258382A3 (en) * 2005-03-31 2014-05-14 Amylin Pharmaceuticals, LLC Amylin and amylin agonists for treating psychiatric diseases and disorders
CN101208098A (zh) * 2005-03-31 2008-06-25 安米林药品公司 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
WO2007055743A2 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
WO2007054809A2 (en) * 2005-11-14 2007-05-18 Rinat Neuroscience Corp. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2010005345A (es) 2007-11-14 2010-08-31 Amylin Pharmaceuticals Inc Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad.
WO2010107874A2 (en) 2009-03-17 2010-09-23 Amylin Pharmaceuticals, Inc. Methods for affecting body composition using amylin agonists
WO2013059336A1 (en) 2011-10-18 2013-04-25 Amylin Pharmaceuticals, Llc Amylin-calcitonin chimeric peptides conjugated to duration enchancing moieties
WO2013112912A1 (en) 2012-01-26 2013-08-01 Soares Christopher J Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
KR102076118B1 (ko) 2012-02-27 2020-02-11 브리스톨-마이어스 스큅 컴퍼니 N-(5S,6S,9R)-5-아미노-6-(2,3-디플루오로페닐)-6,7,8,9-테트라히드로-5H-시클로헵타[b]피리딘-9-일-4-(2-옥소-2,3-디히드로-1H-이미다조[4,5-b]피리딘-1-일)피페리딘-1-카르복실레이트, 헤미술페이트 염

Also Published As

Publication number Publication date
RU2017119773A (ru) 2018-12-06
AU2013211929A1 (en) 2014-09-11
BR112014018284A2 (pt) 2017-07-04
IL233655A (en) 2017-06-29
IL233655A0 (en) 2014-08-31
JP2019006821A (ja) 2019-01-17
DK2807187T3 (en) 2017-09-11
RU2017119773A3 (enExample) 2020-11-18
CN104271596A (zh) 2015-01-07
KR20140132342A (ko) 2014-11-17
JP6411425B2 (ja) 2018-10-24
AU2013211929B2 (en) 2016-05-26
IL252555A0 (en) 2017-07-31
CN104271596B (zh) 2018-09-18
EP3272769B1 (en) 2020-06-17
MX347229B (es) 2017-04-19
EP3272769A1 (en) 2018-01-24
KR20170071613A (ko) 2017-06-23
EP2807187A1 (en) 2014-12-03
CA2861392C (en) 2021-08-17
CA2861392A1 (en) 2013-08-01
RU2014131605A (ru) 2016-03-20
KR101855242B1 (ko) 2018-05-09
RU2624016C2 (ru) 2017-06-30
US9193776B2 (en) 2015-11-24
AU2016205801A1 (en) 2016-08-04
IL252555B (en) 2020-06-30
HK1201068A1 (en) 2015-08-21
JP6025871B2 (ja) 2016-11-16
CN108997490A (zh) 2018-12-14
RU2742826C2 (ru) 2021-02-11
US10370425B2 (en) 2019-08-06
US20160145315A1 (en) 2016-05-26
KR102052983B1 (ko) 2019-12-06
MX2014008960A (es) 2015-01-16
EP2807187B1 (en) 2017-07-26
WO2013112912A1 (en) 2013-08-01
ES2819825T3 (es) 2021-04-19
JP2015513318A (ja) 2015-05-07
HK1249915A1 (en) 2018-11-16
US20140329752A1 (en) 2014-11-06
ES2641325T3 (es) 2017-11-08
JP2017036308A (ja) 2017-02-16
US20170204155A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
BR112014017635A2 (enExample)
BR112014018786A2 (enExample)
BR112014017614A2 (enExample)
BR112014017625A2 (enExample)
BR112014017659A2 (enExample)
BR112014017646A2 (enExample)
BR112014022691A2 (enExample)
BR112014017638A2 (enExample)
AR092201A1 (enExample)
BR112014017609A2 (enExample)
BR112014017634A2 (enExample)
BR112014017644A2 (enExample)
BR112014017938A2 (enExample)
BR112014018029A2 (enExample)
BR112014017618A2 (enExample)
BR112014017647A2 (enExample)
BR112014017623A2 (enExample)
BR112014017652A2 (enExample)
BR112014017630A2 (enExample)
BR112014017621A2 (enExample)
BR112014017631A2 (enExample)
BR112014017641A2 (enExample)
NO2864579T3 (enExample)
BR112014017622A2 (enExample)
BR112014019736A2 (enExample)